Our history and milestones

September – xPIB was selected for the National Biomedical Materials Innovation Task List
April – Clinical research results on the xPIB IOL were released globally at ASCRS 2025
January – Eyedeal was approved to establish the Shaanxi Academician Workstation

November – Research results of the xPIB IOL was presented at he 17th Joint Meeting of China-Japan-Korea Ophthalmologists
November – Eyedeal was awarded the “Bright Merit Award” by the China Health Express Foundation
November – Clinical trial of hydrophobic acrylic toric IOL was completed in China
July – Research results of the xPIB IOL was presented at the 36th  International Congress of Germen Ophthalmic Surgery

December –Clinical trial of the xPIB IOL was completed in China
December – Eyedeal was approved as Shaanxi Demonstration Base for Talent Introduction
August – The xPIB IOL was selected as one of the China’s Top 100 Most Innovative Medical Devices of 2023
April –Eyedeal successfully completed its Series B financing round.
March – Eyedeal was approved to establish the Shaanxi Provincial Engineering Research Center

October – Eyenable® IOL received approval for market launch in China
August – Clinical trial of Eyenable® Toric IOL was initiated in China
May – National Key R&D Program led by Eyedeal successfully passed the final acceptance
March – Eyedeal was approved to establish the Xi’an Engineering Research Center